US equities |
META $620.19 ▼-1.64% MU $928.76 ▲+2.77% NVDA $217.94 ▲+0.90% TSLA $407.46 ▲+4.04% SPCX $148.58 ▲+1.14% AAPL $347.10 ▲+0.93% AMD $560.26 ▲+5.45% MSFT $531.33 ▼-0.24%
FinancialContent

Integra LifeSciences Holdings Corporation - Common Stock (NQ:IART)

11.99 -0.11 (-0.91%)
Delayed Quote Updated: 4:00 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Integra LifeSciences Holdings Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
3 value stocks we find risky
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the... 
Via StockStory
News headline image
IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook
Medical device company Integra LifeSciences (NASDAQ:IART) met Wall Street’s revenue expectations in Q3 2026, with sales up 2.3% year on year to $411.2 millio... 
Via StockStory
News headline image
Integra: 3 Key Takeaways for Long-Term Investors ↗
Operating cash flow hit a record even as the company navigates supply disruptions, a sign of underlying business resilience. 
Via The Motley Fool
Topics Earnings Economy
News headline image
Integra (IART) Q3 2026 Earnings Call Transcript ↗
Cincinnati flooding hit revenue, but neurosurgery growth and refinancing support recovery. 
Via The Motley Fool
Topics Earnings
Integra LifeSciences (NASDAQ:IART) Surges Over 30% on Q2 Earnings Beat ↗
Via Chartmill
News headline image
Why Integra LifeSciences (IART) stock is falling today
What happened? Shares of medical device company Integra LifeSciences (NASDAQ:IART) fell 7.3% in the afternoon session after the company reported third-quarte... 
Via StockStory
News headline image
What Integra LifeSciences (IART) Said on Its Q3 Earnings Call ↗
Integra LifeSciences (NASDAQ:IART) reported third-quarter revenue at the low end of its guidance range as a flooding-related disruption at its Cincinnati facility and slower-than-expected Tissue... 
Via MarketBeat
Topics Earnings Supply Chain
News headline image
Integra LifeSciences (NASDAQ:IART) Posts Q3 2026 Sales In Line With Estimates But Quarterly Revenue Guidance Misses Expectations
Medical device company Integra LifeSciences (NASDAQ:IART) met Wall Street’s revenue expectations in Q3 2026, with sales up 2.3% year on year to $411.2 millio... 
Via StockStory
News headline image
Integra LifeSciences (IART) Q3 Earnings Report Preview: What To Look For
Medical device company Integra LifeSciences (NASDAQ:IART) will be announcing earnings results this Wednesday before market open. Here’s what to look for. Int... 
Via StockStory
News headline image
3 Healthcare Stocks That Concern Us
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme... 
Via StockStory
News headline image
3 Small-Cap Stocks We Approach with Caution
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th... 
Via StockStory
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Why Integra LifeSciences (IART) Stock Is Nosediving
What Happened? Shares of medical device company Integra LifeSciences (NASDAQ:IART) fell 15.3% in the morning session after the company released preliminary t... 
Via StockStory
Friday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
1 of Wall Street’s Favorite Stocks with Impressive Fundamentals and 2 We Turn Down
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
Via StockStory
News headline image
3 Reasons IART is Risky and 1 Stock to Buy Instead
What a time it’s been for Integra LifeSciences. In the past six months alone, the company’s stock price has increased by a massive 70.2%, reaching $16.26 per... 
Via StockStory
Topics Bankruptcy
News headline image
Q2 Earnings Outperformers: Integra LifeSciences (NASDAQ:IART) And The Rest Of The Surgical Equipment & Consumables - Specialty Stocks
Let’s dig into the relative performance of Integra LifeSciences (NASDAQ:IART) and its peers as we unravel the now-completed Q2 surgical equipment & consumabl... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
3 Cash-Producing Stocks That Fall Short
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
Topics Firearms
News headline image
3 Profitable Stocks We Think Twice About
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
News headline image
3 Stocks Under $50 with Questionable Fundamentals
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha... 
Via StockStory
News headline image
3 Value Stocks We Steer Clear Of
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
Via StockStory
News headline image
2 Russell 2000 Stocks with Solid Fundamentals and 1 We Find Risky
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,... 
Via StockStory
News headline image
Integra (IART) Q2 2026 Earnings Call Transcript ↗
Manufacturing restart and margin gains drive stabilization as company pursues deleveraging. 
Via The Motley Fool
Topics Earnings World Trade
News headline image
5 Must-Read Analyst Questions From Integra LifeSciences’s Q2 Earnings Call
Integra LifeSciences’ second quarter results reflected ongoing business challenges, as management attributed the quarter’s flat revenue to ongoing reimbursem... 
Via StockStory
Topics Earnings World Trade
News headline image
IART Q2 Deep Dive: Flat Revenue, Margin Pressure, and Operational Realignment Shape Outlook
Medical device company Integra LifeSciences (NASDAQ:IART) met Wall Street’s revenue expectations in Q2 CY2026, but sales were flat year on year at $418.8 mil... 
Via StockStory
Topics World Trade
News headline image
Why Integra LifeSciences (IART) Shares Are Sliding Today
What Happened? Shares of medical device company Integra LifeSciences (NASDAQ:IART) fell 10.1% in the afternoon session after the company reported a second-qu... 
Via StockStory
Topics Earnings
News headline image
Integra LifeSciences Q2 Earnings Call Highlights ↗
Integra LifeSciences (NASDAQ:IART) reported second-quarter 2026 revenue of $419 million, up 0.8% on a reported basis and 0.7% organically from a year earlier, as improving supply reliability and... 
Via MarketBeat
Topics Earnings World Trade
News headline image
Integra LifeSciences’s (NASDAQ:IART) Q2 CY2026 Earnings Results: Revenue In Line With Expectations
Medical device company Integra LifeSciences (NASDAQ:IART) met Wall Street’s revenue expectations in Q2 CY2026, but sales were flat year on year at $418.8 mil... 
Via StockStory
News headline image
Integra LifeSciences (IART) To Report Earnings Tomorrow: Here Is What To Expect
Medical device company Integra LifeSciences (NASDAQ:IART) will be announcing earnings results this Wednesday morning. Here’s what to look for. Integra LifeSc... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 Next >